Specialist
Former executive at Envision Pharma Group
Agenda
- Market structure dynamics and evolution for medical communications agencies, including demand outlook
- Fishawack’s key service offerings and sources of differentiation among peers, including margin profile across service type
- Fishawack’s AI and digital capabilities and wider market dynamics
- Growth opportunities for Fishawack across inorganic activity & M&A outlook
Questions
1.
Could you start by providing us with an overview of the medical communications services market and what exactly they entail?
2.
How is demand for medical communications services currently trending? How do you expect demand to evolve going forwards?
3.
You mentioned sustainability of demand for medical communications services. Could you delineate across key services and whether we’re seeing demand being strongest or growing the most under a particular type of service vs others?
4.
Looking at a broader trend of seeing pharmaceutical companies having lower R&D investments, how do you see that impacting the demand for medical communications services?
5.
Could you quantify the YoY growth the medical communications services market is seeing? How do you expect it to develop?
6.
According to its website, it seems that Fishawack focuses on a number of core disciplines that range from consulting, to medical, to marketing and policy, value evidence and access. Could you provide an overview of those services? Which one do you see as representing a major revenue driver for the company?
7.
You mentioned Fishawack looking to move from a multichannel to a more omnichannel approach. How successfully do you see the company doing so? How might that compare to what close competitors are doing? How does that fit within pharma companies looking to essentially have fewer providers that offer broader services?
8.
Which service type – from marketing, to medical, to consulting – sees higher margins across medical communications companies?
9.
How comprehensive and diversified do you see the range of services offered by Fishawack to be vs what some of its closest competitors in the field may offer?
10.
Where would you rank Fishawack’s digital competencies or capabilities present in the broader medical communications space in comparison to those of other players that may be more established in providing digital tools or AI for example?
11.
Specialists in previous Forum Interviews essentially noted that the medical communications space is a rather fragmented market. Do you subscribe to that opinion and do you see that changing?
12.
Could we assume that if it is a rather fragmented market that there are low barriers to entry or perhaps otherwise?
13.
You mentioned the operational model for medical communication agencies. Thinking about demand, do you foresee any direct impact on wages for some of these agencies?
14.
You mentioned the broader C> [cell and gene therapy] space becoming increasingly crowded. I’m thinking about large players such as Iqvia. How successfully could a company such as Fishawack compete against any of these large and well-established players? Why would a customer pick it vs others?
15.
It seems that M&A has been part of the key growth strategy for Fishawack, even historically. What is some of your outlook for the company continuing to pursue M&A activity in the mid-term?
